Geneart AG

Geneart AG (FRA:G6A) - European Patent Office grants patent titled "Verfahren für die kontinuierliche, zielgerichtete Evolution von Proteinen in vitro" ("Method for carrying out the selective evolution of proteins in vitro") - A similar patent application for North America is pending - The patent protects GENEART technology for the selected identification of improved protein variants, i.e. for the development of innovative drugs

Geneart AG (FRA:G6A) - New HuCAL PLATINUM® antibody library is based on DNA components synthesized by GENEART - High quality of DNA components produced improves diversity and affinity of antibodies in new HuCAL PLATINUM® - Rational gene sequence design by GENEART's proprietary software GeneOptimizer® leads to significantly higher production rates in tested antibodies - Improved antibody library HuCAL PLATINUM® enables shortening of development timelines, i.e. for the development of promising drug candidates

Geneart AG (OJ:G6A) - The Wellcome Trust Sanger Institute awards a major contract on synthesizing up to 600 genes over the next 10 months to GENEART - The supplied genes will be used in the research program of the Wellcome Trust Sanger Institute - The research program's goal is to identify mechanisms involved in defined genetic and infectious diseases

Geneart AG (OJ:G6A) - Net sales increase by more than 30 % to EUR 11.7M after nine months - Operating result of EUR 1.4M reached the previous year's level - Continued strong growth of small and mid-sized orders - Preliminary results are being confirmed

Geneart AG (OJ:G6A) - GENEART is partner of the iGEM (International Genetically Engineered Machines) contest for the second year in a row - The contest for applications in Synthetic Biology is one of its kind worldwide, and took place for the fifth time - Over 84 student teams from around the world designed cells with useful properties with the help of genetic building blocks - First prizes were awarded for genetic building blocks with potential for medical applications

Geneart AG (OJ:G6A) - Historic event: "Mammalian Gene Collection" completed - For the project GENEART synthesized approx. 2,400 genes - Additional growth impulses expected for the gene synthesis market

Geneart AG (OJ:G6A) - Net sales for 2008 at EUR 11.7M after 9 months - EBIT reaches EUR 1.4M - For the entire year of 2008, net sales between EUR 15.5M and 16.5M are expected with EBIT at prior year's level - Market position was further expanded in slightly weaker market conditions

Geneart AG (OJ:G6A) - GENEART among the top 15 of the fastest growing technology companies in Germany - Among life science companies of this competition, GENEART ranks second - Cumulative corporate growth exceeds 800 percent over the past five years - Targeted investing in automation and process technologies allows further increase in capacities

Geneart AG (OJ:G6A) - Ernst & Young honours Germany's best mid-tier companies - Impressive growth rates and high innovative strength lead GENEART AG's team into the final - Prestigious business award will be presented at the Alte Oper Frankfurt on October 9, 2008.

Geneart AG (OJ:G6A) - GENEART wins "European Biotechnica Award", awarded by the Deutsche Messe AG and its partners - The award is honouring high innovative strength and a powerful business concept - The prestigious prize comprises of cash and non-cash benefits totalling EUR 100,000 - The British company Astex Therapeutics Limited and the German company immatics biotechnologies GmbH were honoured as finalists